AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32453368
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication reduction (removal of 1 drug), n=282
Trial: 32453368
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no medication changes), n=287
Trial: 32127890
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion (TCI) of propofol with an initial target effect‐site concentration of 4mcg/ml, followed by maintenance at 2.5mcg/ml, titrated by 0.5mcg/ml as needed.
Trial: 32127890
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion (TCI) of propofol.
Trial: 34508557
Drug: High-dose SM03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SM03 (3600 mg, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14, and 16)
Trial: 34508557
Drug: Low-dose SM03
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SM03 (2400 mg, 600 mg × 4 infusions at weeks 0, 2, 12, and 14)
Trial: 34508557
Drug: High-dose SM03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SM03
Trial: 34508557
Drug: Low-dose SM03
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SM03
Trial: 34508557
Drug: SM03 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM03 (both doses)
Trial: 36470677
Drug: Fostamatinib (100-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (100-150 mg twice a day for 24 weeks)
Trial: 35856162
Drug: Terlipressin (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1.3 μg/kg/hour for 24 h)
Trial: 34871513
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of nicorandil
Trial: 32546247
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) initiated within 24 hours after PICU admission
Trial: 32546247
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) withheld for up to 1 week in the PICU
Trial: 33963911
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of alteplase
Trial: 38677714
Drug: Early antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antibiotic exposure
Trial: 33453456
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1.5 g/6 h)
Trial: 32130809
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir and rilpivirine (monthly intramuscular injections)
Trial: 32130809
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (standard antiretroviral therapy)
Trial: 35559498
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone acetonide (GC group)
Trial: 35000582
Drug: Honey medicinal
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey medicinal gel (unheated natural honey)
Trial: 34048095
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment for 2 weeks
Trial: 33045769
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (CV; tidal volume of 9‐10 mL/kg predicted body weight with no positive end‐expiratory pressure)
Trial: 33045769
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation (PV; tidal volume of 6‐8 mL/kg predicted body weight and 5 cmH₂O PEEP)
Trial: 34663784
Drug: Yohimbine administration
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine administration
Trial: 33857914
Drug: Qing-Chang-Hua-Shi granules
RxNorm normalized name: Shi Liu Fruit
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qing-Chang-Hua-Shi granules (125 g/day)
Trial: 33857914
Drug: Placebo (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (125 g/day)
Trial: 36272243
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel added to the interrupted microdose flare protocol
Trial: 34619734
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 1 g (group 1)
Trial: 34619734
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 1 g with oral amoxicillin 2 g (group 2)
Trial: 32161233
Drug: CHX 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX 0.12% mouthrinse (twice daily, 10 mL rinse for 30 s)
Trial: 32161233
Drug: CHX 0.20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX 0.20% mouthrinse (twice daily, 10 mL rinse for 30 s)
Trial: 32161233
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical treatment (Control group)
Trial: 32200009
Drug: Combined bleaching
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bleaching (CB) treatment
Trial: 33583390
Drug: Sofosbuvir-based therapy
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-based therapy
Trial: 35137022
Drug: Psychological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological interventions to optimize treatment expectations (IA group, n = 30)
Trial: 35137022
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention (IB group, n = 29) with psychological interventions plus additional treatment package
Trial: 35501082
Drug: Antianaerobic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianaerobic antibiotics
Trial: 34515439
Drug: Saline enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline enemas twice daily until normal stooling pattern achieved (Group 1)
Trial: 32888740
Drug: Pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent vaccine (Quinvaxem)
Trial: 32888740
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine (Infanrix-hexa)
Trial: 32888740
Drug: Pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent vaccine (Quinvaxem) among TT-vaccinated mothers
Trial: 34529839
Drug: Flurbiprofen tablets
RxNorm normalized name: Flurbiprofen Tablets
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen tablets (FPT)
Trial: 32385508
Drug: Intravenous delta-9-tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous delta-9-tetrahydrocannabinol (THC)
Trial: 33177437
Drug: Study treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatments (both interventions)
Trial: 33025843
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Hyperthermia
Trial: 33631065
Drug: Pooled interleukin-6
RxNorm normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled interleukin-6 receptor antagonists (tocilizumab and sarilumab)
Trial: 32867199
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA supplementation (2.6 g EPA and 1.8 g DHA)
Trial: 33561964
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran dietary intervention (30 g over 24 hours for 24 weeks)
Trial: 33561964
Drug: Rice powder
RxNorm normalized name: White rice powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice powder (control group, 30 g over 24 hours for 24 weeks)
Trial: 32186960
Drug: IL-4 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-4 gene rs2243291 genotype (C/G)
Trial: 34526095
Drug: Early pharmacological
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early pharmacological treatment with ibuprofen (administered 24-72 hours postnatal age)
Trial: 34526095
Drug: Early pharmacological
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early pharmacological treatment with ibuprofen
Trial: 32452128
Drug: Spironolactone (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (median dose 22.5 mg/day)
Trial: 32452128
Drug: Placebo (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (median dose 27.5 mg/day)
Trial: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (TOF) 5 or 10 mg BID
Trial: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (TOF) 5 mg BID
Trial: 35232809
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (TOF) 5 mg BID with methotrexate (MTX)
Trial: 35973146
Drug: Biologics fact
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics fact sheet
Trial: 32118387
Drug: Interdisciplinary Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary Treatment (INTER)
Trial: 34433772
Drug: Personalized opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized opioid tapering plan
Trial: 33465342
Drug: High-dose prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose)
Trial: 33465342
Drug: High-dose prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prophylactic anticoagulation
Trial: 35551374
Drug: Extended-Release Calcifediol
RxNorm normalized name: calcifediol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Calcifediol (ERC) treatment (60 μg/day) for 8 weeks
Trial: 35551374
Drug: Extended-Release Calcifediol
RxNorm normalized name: calcifediol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release Calcifediol (ERC) treatment (30 or 60 μg/day)
Trial: 35551374
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplements (cholecalciferol or ergocalciferol)
Trial: 32303700
Drug: Biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agents with different modes of action
Trial: 32303700
Drug: Aminosalicylate therapy
RxNorm normalized name: aminosalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminosalicylate therapy
Trial: 35845502
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure (SAA) combined with usual care
Trial: 35133113
Drug: Bimekizumab self-injection
RxNorm normalized name: bimekizumab Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab self-injection using safety syringe
Trial: 35133113
Drug: Bimekizumab self-injection
RxNorm normalized name: bimekizumab Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab self-injection using auto-injector
Trial: 35133113
Drug: Bimekizumab self-injection
RxNorm normalized name: bimekizumab Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab self-injection at Baseline (both devices)
Trial: 35593915
Drug: Oral delta‐9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC) 7.5 mg
Trial: 35593915
Drug: Oral delta‐9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delta‐9‐tetrahydrocannabinol (THC) 15 mg
Trial: 35593915
Drug: THC (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (7.5 mg and 15 mg)
Trial: 34766228
Drug: Stachys schtschegleevii
RxNorm normalized name: Stachys officinalis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stachys schtschegleevii tea (2.4 g/day SSC + 2.4 g/day black tea)
Trial: 34766228
Drug: Placebo (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.4 g/day black tea)
Trial: 35023026
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care and anticoagulation therapy
Trial: 33729391
Drug: Exercise Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Training (ET) - 3 weekly sessions of aerobic exercise, local strengthening, and stretching exercises (72 sessions over 40±3.9 weeks)
Trial: 36096746
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3D virtual reality and hands-on horticultural activities (8-week intervention)
Trial: 32056311
Drug: Naltrexone, acamprosate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone, acamprosate, or placebo with combined behavioral intervention or medication management in COMBINE
Trial: 32056311
Drug: Social behavior
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social behavior network therapy or motivational enhancement therapy in UKATT
Trial: 35410334
Drug: PD-(L)1 blockade
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-(L)1 blockade in patients with brain and adrenal gland metastases
Trial: 35410334
Drug: PD-(L)1 blockade
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-(L)1 blockade in PD-L1-positive populations (PD-L1 > 1%)
Trial: 35410334
Drug: METscore in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METscore in patients receiving PD-(L)1 blockade
Trial: 35410334
Drug: PD-(L)1 blockade
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-(L)1 blockade as first-line treatment in clinical trials
Trial: 35410334
Drug: PD-(L)1 blockade
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-(L)1 blockade as first-line treatment in real-world practice
Trial: 35410334
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with various metastatic sites
Trial: 36302890
Drug: Molecular testing
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular testing and targeted therapy (specific details not provided)
Trial: 33803951
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder (0.5 g/kg)
Trial: 33803951
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder (1 g/kg)
Trial: 33803951
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder (1.5 g/kg)
Trial: 33803951
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder (0.5, 1, and 1.5 g/kg)
Trial: 35354410
Drug: baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baricitinib 2 mg
Trial: 35354410
Drug: baricitinib 1
RxNorm normalized name: baricitinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baricitinib 1 mg
Trial: 35354410
Drug: baricitinib 1
RxNorm normalized name: baricitinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baricitinib 1 mg and 2 mg
Trial: 35354410
Drug: baricitinib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baricitinib (1 mg and 2 mg)
Trial: 35595197
Drug: Increased FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased FSH dosing (300 IU/day for AFC 1-6, 225 IU/day for AFC 7-9)
Trial: 35595197
Drug: Standard FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FSH dosing (150 IU/day)
Trial: 35595197
Drug: Increased FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased FSH dosing
Trial: 35595197
Drug: Standard FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FSH dosing
Trial: 34005830
Drug: Modified glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified glycoprotein plant extract (blocker) added to polysensitised samples
Trial: 36050448
Drug: Trastuzumab (T)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (T) + chemotherapy
Trial: 32161453
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group 1 (H1, 8 mg/day, 2 mg Q6h)
Trial: 32161453
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group 2 (H2, 8 mg/day, 4 mg Q12h)
Trial: 32161453
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group (L, 4 mg/day, 1 mg Q6h)
Trial: 34793687
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - mometasone, 200 μg or 220 μg twice daily
Trial: 34793687
Drug: Long-acting muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonists (LAMA) - tiotropium, 5 μg daily
Trial: 34535755
Drug: Digital Diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Diabetes Intervention (monthly messages through an online health platform)
Trial: 35953808
Drug: Switching antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching antipsychotic medication
Trial: 35868244
Drug: 1-hour sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour sound therapy
Trial: 35868244
Drug: 3-hour sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hour sound therapy
Trial: 35868244
Drug: 5-hour sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hour sound therapy
Trial: 34275783
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with hydralazine and sodium nitroprusside
Trial: 35041634
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg once daily for 30 days
Trial: 32979860
Drug: Erythromycin ointment
RxNorm normalized name: Erythromycin Ointment
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ointment
Trial: 34326841
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Naltrexone (LDN, 3.0–5.0 mg/day)
Trial: 34326841
Drug: Ononetin (TRPM3-antagonist)
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ononetin (TRPM3-antagonist)
Trial: 36474100
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (bLF) 600 mg daily for 90 days
Trial: 34803424
Drug: Rg3-enriched Korean
RxNorm normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rg3-enriched Korean Red Ginseng (Rg3-KRG) + American Ginseng (AG) at 2.25 g/day
Trial: 35523395
Drug: Chaiqin Qingning
RxNorm normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaiqin Qingning Capsule (CQQNC)
Trial: 35523395
Drug: Qingkailing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing Capsule (QKLC)
Trial: 33907786
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of far-distal orthodontic force
Trial: 33907786
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of far-distal orthodontic force
Trial: 33907786
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g of far-distal orthodontic force
Trial: 33907786
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of far-distal orthodontic force